UK Supreme Court strikes down Regeneron patents, opening door for Kymab
The UK Supreme Court has struck down a pair of Regeneron patents, all but ending a legal dispute between the large US biotech and an upstart British competitor that has raged since 2013.
In a 4-1 ruling, the judges held that the patents Regeneron filed on a technique necessary to make their antibody-producing mice didn’t provide enough information for an expert in the field to reproduce all the inventions covered in the claim. The ruling overturned an appellate court decision that held in favor of Regeneron and against the Cambridge-based Kymab.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 84,800+ biopharma pros reading Endpoints daily — and it's free.